Viewing StudyNCT04003636



Ignite Creation Date: 2024-05-06 @ 1:23 PM
Last Modification Date: 2024-10-26 @ 1:13 PM
Study NCT ID: NCT04003636
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-03-05
First Post: 2019-06-28

Brief Title: Pembrolizumab MK-3475 Plus GemcitabineCisplatin Versus Placebo Plus GemcitabineCisplatin for First-Line Advanced andor Unresectable Biliary Tract Carcinoma BTC MK-3475-966KEYNOTE-966
Sponsor:
Organization: Merck Sharp Dohme LLC

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 1069
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: